Courtesy Story | Defense Threat Reduction Agency's Chemical and Biological Technologies Department | 01.06.2024
Biothreats persist in their pursuit; developing new antibiotics is a way to stay ahead. Researchers are developing new antibiotics to combat common bacteria that are becoming increasingly resistant to antibiotic treatment, which is a growing concern for both public health and Joint Force readiness. Both emerging pathogens and known biothreats, such as Bacillus anthracis (anthrax), pestis......
Courtesy Story | Defense Threat Reduction Agency's Chemical and Biological Technologies Department | 04.11.2023
Biomarkers of the body’s natural responses indicate whether an infection is viral or bacterial. MeMed’s Key is the latest way to listen to what the body is telling us. A new diagnostic test can quickly determine if an illness with a fever is caused by a bacterial versus a viral infection, an important distinction in speeding up administering the appropriate treatment. Additionally, it......
Story by Claudia Sanchez-Bustamante | Defense Health Agency | 11.10.2021
As use of life-saving antibiotics has increased around the world, some bacteria are becoming resistant to this type of medication. Those antibiotic-resistant bacteria can evolve into so-called superbugs, which can spread and become more dangerous....
Courtesy Story | Defense Threat Reduction Agency's Chemical and Biological Technologies Department | 09.08.2021
Uncovering the way E. coli resists antibiotics may lead to new therapeutics. Researchers are making significant progress in antibiotic resistance under the Discovery of Medical Countermeasures Against New and Emerging threats (DOMANE) program of the Defense Threat Reduction Agency’s (DTRA) Chemical and Biological Technologies Department in its role as the Joint Science and Technology......
Courtesy Story | Defense Threat Reduction Agency's Chemical and Biological Technologies Department | 10.15.2018
The Joint Science and Technology Office (JSTO) Science Review (JSR) fosters collaboration, cooperation and innovation by allowing program managers and senior leadership to understand the latest warfighter-driven technologies in development....
Courtesy Story | Defense Threat Reduction Agency's Chemical and Biological Technologies Department | 10.15.2018
DNA-based nucleic acid vaccines have the potential to become a universal platform solution to viral threat agents. The U.S. Department of Defense is currently developing DNA vaccines to protect against a variety of viral threats including alphaviruses, filoviruses and hantaviruses....
Courtesy Story | Defense Threat Reduction Agency's Chemical and Biological Technologies Department | 10.15.2018
When Ebola virus disease (EVD) reared its head in May in the Congo, the world was armed with the rVSV-ZEBOV vaccine thanks to interagency collaboration efforts by the Defense Threat Reduction Agency’s Chemical and Biological Technologies Department....
Courtesy Story | Defense Threat Reduction Agency's Chemical and Biological Technologies Department | 10.24.2017
Share innovative ideas with more than 1,500 of the most influential scientists, program managers and leaders in the defense community at the 2017 Chemical and Biological Defense Science & Technology (CBD S&T) Conference Nov. 28-30, 2017, in Long Beach, Calif....
